COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,159 Articles (22,703 medRxiv, 8,456 bioRxiv)

Most recent first Previous |  Page 1451: Articles 14501-14510  | Next

Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study
Abdoli, A., Aalizadeh, R., Aminianfar, H.
10.1101/2021.06.10.447951 — Posted: 2021-06-10 Discussion: Onsite
MPI8 is Potent Against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L
Ma, X. R., Alugubelli, Y. R., Ma, Y., Vatansever, E. C., Scott, D. A., Qiao, Y., Yu, G., Xu, S., Liu, W. R.
10.1101/2021.06.10.447950 — Posted: 2021-06-10
Evaluating the utility of high-resolution proximity metrics in predicting the spread of COVID-19
Mehrab, Z., Adiga, A., Marathe, M., Venkatramanan, S., Swarup, S.
10.1101/2021.06.07.21258492 — Posted: 2021-06-10
A functionally distinct neutrophil landscape in severe COVID-19 reveals opportunities for adjunctive therapies
Panda, R., Castanheira, F. V. E. S., Schlechte, J., Surewaard, B. G., Shim, H. B., Zucoloto, A. Z., Slavikova, Z., Yipp, B. G., Kubes, P., McDonald, B.
10.1101/2021.06.07.21258484 — Posted: 2021-06-10
Inferring global-scale temporal latent topics from news reports to predict public health interventions for COVID-19
Wen, Z., Powell, G., Chafi, I., Buckeridge, D., Li, Y.
10.1101/2021.06.10.21257749 — Posted: 2021-06-10
Immunity to SARS-CoV-2 persists 9 months post-symptoms with an altered T cell phenotype compared to influenza A virus-specific memory
Law, J. C., Girard, M., Chao, G. Y. C., Ward, L. A., Isho, B., Rathod, B., Colwill, K., Li, Z., Rini, J. M., Yue, F. Y., Mubareka, S., McGeer, A. J., Ostrowski, M. A., Gommerman, J. L., Gingras, A.-C., Watts, T. H.
10.1101/2021.06.08.21258518 — Posted: 2021-06-10
Social inequalities in hostility toward vaccination against Covid-19
Spire, A., Silberzan, L., Bajos, N., The EpiCov study group
10.1101/2021.06.07.21258461 — Posted: 2021-06-10 Discussion: Onsite
Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics
Dyson, L., Hill, E. M., Moore, S., Curran-Sebastian, J., Tildesley, M. J., Lythgoe, K. A., House, T., Pellis, L., Keeling, M. J.
10.1101/2021.06.07.21258476 — Posted: 2021-06-10
The impact of COVID-19 pandemic on influenza transmission: molecular and epidemiological evidence
Tran, L. K., Huang, D.-W., Li, N.-K., Palacios, J., Chang, H.-H., Li, L. M.
10.1101/2021.06.08.21258434 — Posted: 2021-06-10
Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?
Takeuchi, M., Higa, Y., Esaki, A., Nabeshima, Y., Nakazono, A.
10.1101/2021.06.08.21258444 — Posted: 2021-06-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).